Trademarkia Logo

Canada

C$
MYFEMBREE
APPROVED

on 27 May 2025

Last Applicant/ Owned by

Sumitomo Pharma Switzerland GmbH

Aeschengraben 27,4051 Basel

CH

Serial Number

2093766 filed on 22nd Mar 2021

Correspondent Address

GOWLING WLG (CANADA) LLP

SUITE 2600, 160 ELGIN STREETOTTAWA

ONTARIO

CA

K1P1C3

MYFEMBREE

Trademark usage description

providing health and medical information in the fields of women's health, fertility treatments, pharmaceutical advice in the nature of information rel Read More

Classification Information


Class [044]
Providing health and medical information in the fields of women's health, fertility treatments, pharmaceutical advice in the nature of information relating to diagnostic, prophylactic and therapeutic properties of pharmaceuticals, medical treatment services, and disease management in the fields of oncology, endocrinology, and in treatment of hormone related diseases and conditions and in treatment of women's health issues, namely, infertility, uterine fibroids and symptoms thereof, endometriosis and symptoms thereof, and symptoms of menopause; providing information relating to the diagnostic, prophylactic and therapeutic properties of pharmaceutical preparations and biologic preparations for the prevention and treatment of diseases, disorders and conditions.


Classification kind code

11

Mark Details


Serial Number

2093766

Mark Type

Trademark

Legal History


Action TakenStatus
Submitted for opposition 26
on 27th May 2025
Approved
Submitted for opposition 27
on 27th May 2025
Approval Notice Sent
Submitted for opposition 15
on 14th Nov 2024
Correspondence Created
Submitted for opposition 135
on 16th Jul 2024
Amendment to Application
Submitted for opposition 22
on 19th Mar 2024
Search Recorded
Submitted for opposition 20
on 19th Mar 2024
Examiner's First Report
Submitted for opposition 287
on 29th Jun 2022
Pre-Assessment Letter Sent
Submitted for opposition 30
on 22nd Mar 2021
Filed
Submitted for opposition 1
on 22nd Mar 2021
Created
Submitted for opposition 31
on 22nd Mar 2021
Formalized